Cortexyme (CRTX) Competitors $1.02 +0.02 (+2.00%) As of 04/14/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesTrendsBuy This Stock CRTX vs. OMCL, HSTM, MDRX, FENC, IPHA, MOLN, TARA, IKT, FDMT, and NMRAShould you be buying Cortexyme stock or one of its competitors? The main competitors of Cortexyme include Omnicell (OMCL), HealthStream (HSTM), Veradigm (MDRX), Fennec Pharmaceuticals (FENC), Innate Pharma (IPHA), Molecular Partners (MOLN), Protara Therapeutics (TARA), Inhibikase Therapeutics (IKT), 4D Molecular Therapeutics (FDMT), and Neumora Therapeutics (NMRA). Cortexyme vs. Omnicell HealthStream Veradigm Fennec Pharmaceuticals Innate Pharma Molecular Partners Protara Therapeutics Inhibikase Therapeutics 4D Molecular Therapeutics Neumora Therapeutics Cortexyme (NASDAQ:CRTX) and Omnicell (NASDAQ:OMCL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership, community ranking and risk. Does the MarketBeat Community favor CRTX or OMCL? Omnicell received 348 more outperform votes than Cortexyme when rated by MarketBeat users. Likewise, 66.84% of users gave Omnicell an outperform vote while only 64.44% of users gave Cortexyme an outperform vote. CompanyUnderperformOutperformCortexymeOutperform Votes15464.44% Underperform Votes8535.56% OmnicellOutperform Votes50266.84% Underperform Votes24933.16% Do analysts prefer CRTX or OMCL? Omnicell has a consensus price target of $51.00, indicating a potential upside of 62.68%. Given Omnicell's stronger consensus rating and higher possible upside, analysts plainly believe Omnicell is more favorable than Cortexyme.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cortexyme 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Omnicell 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media prefer CRTX or OMCL? In the previous week, Omnicell had 11 more articles in the media than Cortexyme. MarketBeat recorded 11 mentions for Omnicell and 0 mentions for Cortexyme. Omnicell's average media sentiment score of 1.03 beat Cortexyme's score of 0.00 indicating that Omnicell is being referred to more favorably in the news media. Company Overall Sentiment Cortexyme Neutral Omnicell Positive Do insiders and institutionals have more ownership in CRTX or OMCL? 63.2% of Cortexyme shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 27.9% of Cortexyme shares are owned by insiders. Comparatively, 2.6% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, CRTX or OMCL? Cortexyme has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Which has preferable valuation and earnings, CRTX or OMCL? Omnicell has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCortexymeN/AN/A-$89.94M-$2.97-0.34Omnicell$1.11B1.32$12.53M$0.27116.11 Is CRTX or OMCL more profitable? Omnicell has a net margin of 1.13% compared to Cortexyme's net margin of 0.00%. Omnicell's return on equity of 3.82% beat Cortexyme's return on equity.Company Net Margins Return on Equity Return on Assets CortexymeN/A -70.96% -63.53% Omnicell 1.13%3.82%2.07% SummaryOmnicell beats Cortexyme on 15 of the 17 factors compared between the two stocks. Remove Ads Get Cortexyme News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRTX vs. The Competition Export to ExcelMetricCortexymeBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.75M$2.90B$5.33B$7.57BDividend YieldN/A1.91%5.11%4.32%P/E Ratio-0.3431.0021.7217.82Price / SalesN/A441.16376.8894.61Price / CashN/A168.6838.1534.64Price / Book0.263.476.474.00Net Income-$89.94M-$72.06M$3.20B$247.23M7 Day Performance-8.93%3.17%2.86%1.45%1 Month Performance-29.17%-16.97%-8.55%-6.24%1 Year Performance1.49%-29.07%10.58%0.60% Cortexyme Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRTXCortexymeN/A$1.02+2.0%N/A+1.5%$30.75MN/A-0.3455Gap UpOMCLOmnicell2.3423 of 5 stars$31.60-3.3%$51.00+61.4%+16.6%$1.48B$1.11B117.043,800Analyst UpgradeShort Interest ↑Positive NewsHSTMHealthStream3.5703 of 5 stars$30.63-2.0%$32.00+4.5%+33.0%$932.19M$291.65M47.121,140Positive NewsMDRXVeradigm2.044 of 5 stars$3.90-2.5%$14.00+259.0%-44.7%$422.23M$1.53B0.008,000Gap UpFENCFennec Pharmaceuticals1.6657 of 5 stars$5.21-0.8%$13.67+162.3%-49.2%$143.73M$47.54M-52.09N/AGap DownIPHAInnate Pharma2.8233 of 5 stars$1.71-6.6%$11.50+572.5%-21.1%$143.35M$12.63M0.00220News CoverageGap DownMOLNMolecular Partners2.2847 of 5 stars$3.54-0.8%$12.00+239.0%-4.9%$142.93M$4.97M-1.65180Upcoming EarningsTARAProtara Therapeutics1.9964 of 5 stars$3.70-5.1%$22.50+508.1%+46.8%$136.04MN/A-1.3130Gap DownIKTInhibikase Therapeutics1.4382 of 5 stars$1.68-8.7%$6.50+286.9%-13.4%$124.90M$260,000.00-0.636FDMT4D Molecular Therapeutics2.584 of 5 stars$2.65-4.3%$26.71+908.1%-88.2%$122.70M$37,000.00-0.93120Positive NewsGap DownNMRANeumora Therapeutics3.108 of 5 stars$0.75+2.3%$9.29+1,132.8%-94.1%$122.00MN/A-0.40108 Remove Ads Related Companies and Tools Related Companies Omnicell Alternatives HealthStream Alternatives Veradigm Alternatives Fennec Pharmaceuticals Alternatives Innate Pharma Alternatives Molecular Partners Alternatives Protara Therapeutics Alternatives Inhibikase Therapeutics Alternatives 4D Molecular Therapeutics Alternatives Neumora Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRTX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortexyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRTX Stock Free CRTX Stock Alerts